166 related articles for article (PubMed ID: 10656730)
1. Uterine smooth muscle tumors: utility of classification by proliferation, ploidy, and prognostic markers versus traditional histopathology.
Layfield LJ; Liu K; Dodge R; Barsky SH
Arch Pathol Lab Med; 2000 Feb; 124(2):221-7. PubMed ID: 10656730
[TBL] [Abstract][Full Text] [Related]
2. Comparison of argyrophilic nucleolar organizer regions (AgNORs) and mitotic index in distinguishing benign from malignant canine smooth muscle tumors and in separating inflammatory hyperplasia from neoplastic lesions of the urinary bladder mucosa.
Johnson GC; Miller MA; Ramos-Vara JA
J Vet Diagn Invest; 1995 Jan; 7(1):127-36. PubMed ID: 7779947
[TBL] [Abstract][Full Text] [Related]
3. Leiomyosarcoma of the uterus: A clinicopathologic, DNA flow cytometric, p53, and mdm-2 analysis of 49 cases.
Blom R; Guerrieri C; Stâl O; Malmström H; Simonsen E
Gynecol Oncol; 1998 Jan; 68(1):54-61. PubMed ID: 9454661
[TBL] [Abstract][Full Text] [Related]
4. MIB-1 (Ki-67), p53, estrogen receptor, and progesterone receptor expression in uterine smooth muscle tumors.
Mittal K; Demopoulos RI
Hum Pathol; 2001 Sep; 32(9):984-7. PubMed ID: 11567229
[TBL] [Abstract][Full Text] [Related]
5. Proliferation, ploidy and prognosis in uterine smooth muscle tumours.
Jeffers MD; Oakes SJ; Richmond JA; Macaulay EM
Histopathology; 1996 Sep; 29(3):217-23. PubMed ID: 8884349
[TBL] [Abstract][Full Text] [Related]
6. Uterine leiomyosarcomas are characterized by high p16, p53 and MIB1 expression in comparison with usual leiomyomas, leiomyoma variants and smooth muscle tumours of uncertain malignant potential.
O'Neill CJ; McBride HA; Connolly LE; McCluggage WG
Histopathology; 2007 Jun; 50(7):851-8. PubMed ID: 17543074
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of proliferative activity of ovarian carcinoma as revealed by PCNA and AgNOR analyses.
Ghazizadeh M; Sasaki Y; Araki T; Konishi H; Aihara K
Am J Clin Pathol; 1997 Apr; 107(4):451-8. PubMed ID: 9124214
[TBL] [Abstract][Full Text] [Related]
8. The prognostic significance of stage, tumor size, cellular atypia and DNA ploidy in uterine leiomyosarcoma.
Nordal RR; Kristensen GB; Kaern J; Stenwig AE; Pettersen EO; Tropé CG
Acta Oncol; 1995; 34(6):797-802. PubMed ID: 7576748
[TBL] [Abstract][Full Text] [Related]
9. [Usefulness of DNA ploidy, AgNORs, PCNA and c-erbB-2 as predictors of prognosis in patients with renal cell carcinoma].
Tamaki M; Maeda S; Deguchi T; Kawada Y
Hinyokika Kiyo; 1997 Oct; 43(10):697-702. PubMed ID: 9395903
[TBL] [Abstract][Full Text] [Related]
10. Malignant mixed Müllerian tumors of the uterus: a clinicopathologic, DNA flow cytometric, p53, and mdm-2 analysis of 44 cases.
Blom R; Guerrieri C; Stâl O; Malmström H; Sullivan S; Simonsen E
Gynecol Oncol; 1998 Jan; 68(1):18-24. PubMed ID: 9454654
[TBL] [Abstract][Full Text] [Related]
11. Smooth muscle tumors of the gastrointestinal tract: analysis of prognostic factors.
Chou FF; Eng HL; Sheen-Chen SM
Surgery; 1996 Feb; 119(2):171-7. PubMed ID: 8571202
[TBL] [Abstract][Full Text] [Related]
12. The Use of p16 in enhancing the histologic classification of uterine smooth muscle tumors.
Atkins KA; Arronte N; Darus CJ; Rice LW
Am J Surg Pathol; 2008 Jan; 32(1):98-102. PubMed ID: 18162776
[TBL] [Abstract][Full Text] [Related]
13. A comparative assessment of proliferating cell nuclear antigen, c-myc p62, and nucleolar organizer region staining in non-Hodgkin's lymphomas: a histochemical and immunohistochemical study of 200 cases.
Korkolopoulou P; Patsouris E; Pangalis G; Tsenga A; Elemenoglou J; Thomas-Tsangli E; Spandidos D; Kittas C
Hum Pathol; 1993 Apr; 24(4):371-7. PubMed ID: 7684020
[TBL] [Abstract][Full Text] [Related]
14. A new scoring system using multiple immunohistochemical markers for diagnosis of uterine smooth muscle tumors.
Rath-Wolfson L; Rosenblat Y; Halpern M; Herbert M; Hammel I; Gal R; Leabu M; Koren R
J Cell Mol Med; 2006; 10(1):197-205. PubMed ID: 16563231
[TBL] [Abstract][Full Text] [Related]
15. A panel of antibodies to determine site of origin and malignancy in smooth muscle tumors.
Lee CH; Turbin DA; Sung YC; Espinosa I; Montgomery K; van de Rijn M; Gilks CB
Mod Pathol; 2009 Dec; 22(12):1519-31. PubMed ID: 19734847
[TBL] [Abstract][Full Text] [Related]
16. Leiomyosarcoma versus bizarre and cellular leiomyomas of the uterus: a comparative study based on the MIB-1 and proliferating cell nuclear antigen indices, p53 expression, DNA flow cytometry, and muscle specific actins.
Amada S; Nakano H; Tsuneyoshi M
Int J Gynecol Pathol; 1995 Apr; 14(2):134-42. PubMed ID: 8601525
[TBL] [Abstract][Full Text] [Related]
17. An immunohistochemical analysis of stathmin 1 expression in uterine smooth muscle tumors: differential expression in leiomyosarcomas and leiomyomas.
Allen MM; Douds JJ; Liang SX; Desouki MM; Parkash V; Fadare O
Int J Clin Exp Pathol; 2015; 8(3):2795-801. PubMed ID: 26045786
[TBL] [Abstract][Full Text] [Related]
18. Problematic uterine smooth muscle neoplasms. A clinicopathologic study of 213 cases.
Bell SW; Kempson RL; Hendrickson MR
Am J Surg Pathol; 1994 Jun; 18(6):535-58. PubMed ID: 8179071
[TBL] [Abstract][Full Text] [Related]
19. Quantitative pathology in uterine smooth muscle tumours: the case for the standard histologic classification criteria.
Soumakis S; Panayiotides J; Protopapa E; Kouri E; Vlachonikolis J; Delides GS
Eur J Gynaecol Oncol; 1997; 18(3):203-7. PubMed ID: 9174837
[TBL] [Abstract][Full Text] [Related]
20. Morphometric determination of AgNORs in breast carcinoma. Correlation with flow cytometry and proliferating cell nuclear antigen.
Bellotti M; Elsner B; Kahn A; Bezodnick L; Pisilli L; Greco P
Anal Quant Cytol Histol; 1997 Apr; 19(2):139-44. PubMed ID: 9113306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
